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Abstract
 
Human histocompatibility leukocyte antigen (HLA)-DO, a lysosomal resident major histo-
compatibility complex class II molecule expressed in B cells, has previously been shown to be a
negative regulator of HLA-DM peptide loading function. We analyze the expression of DO in
human peripheral blood, lymph node, tonsil, and bone marrow to determine if DO expression
is modulated in the physiological setting. B cells, but not monocytes or monocyte-derived den-
dritic cells, are observed to express this protein. Preclearing experiments demonstrate that
 
 
 
50% of HLA-DM is bound to DO in peripheral blood B cells. HLA-DM and HLA-DR ex-
pression is demonstrated early in B cell development, beginning at the pro-B stage in adult hu-
man bone marrow. In contrast, DO expression is initiated only after B cell development is
complete. In all situations, there is a striking correlation between intracellular DO expression
and cell surface class II–associated invariant chain peptide expression, which suggests that DO
substantially inhibits DM function in primary human B cells. We report that the expression of
DO is markedly downmodulated in human germinal center B cells. Modulation of DO ex-
pression may provide a mechanism to regulate peptide loading activity and antigen presentation
by B cells during the development of humoral immune responses.
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Introduction
 
MHC class II 
 
  
 
 molecules assemble with the chaperone
protein, invariant chain (Ii),
 
*
 
 in the endoplasmic reticulum
(1). An unstructured segment of Ii, encoded by exon 3,
occupies the 
 
  
 
 peptide binding site, which helps stabilize
the newly assembled complex. After transport to endoso-
mal compartments, most of the Ii protein is released from
 
  
 
 through a series of proteolytic cleavage events, leaving a
fragment of Ii, class II–associated Ii peptide (CLIP), buried
in the peptide binding site (2–4). HLA-DM (H2-M in
mice) is a key component of the MHC class II antigen–
processing pathway (5). Although this lysosomal resident
protein is structurally similar to other class II molecules, it
has limited polymorphism and does not bind peptide anti-
gens. Its major function is to catalyze peptide binding and
exchange reactions in other class II molecules (6–8). Cell
surface class II molecules are predominantly occupied by
CLIP in DM-deficient APC (2, 3, 9–11). Thus, a major
function of DM is to catalyze the release of CLIP and the
binding of peptide antigens present in endosomal compart-
ments. DM can also catalyze further rounds of peptide ex-
change, markedly influencing the repertoire of peptides
displayed at the cell surface and favoring the most stable
peptide complexes (12–14).
Like DM, HLA-DO is a lysosomal resident MHC class
II protein with limited polymorphism. However, early
studies demonstrated that the murine homologue of DO
(H2-O) is selectively expressed in B cells and a subset of
thymic epithelial cells, but not in other APC (15, 16). Thus
DO must have a specialized function, rather than a general
role in the class II antigen–processing pathway. In the ab-
sence of DM, DO appears to be an intrinsically unstable
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molecule, rapidly degraded (17). DO binds stably to DM in
the endoplasmic reticulum, and DO–DM complexes are
transported to lysosome-related compartments through a
targeting signal in the DM
 
 
 
 chain cytoplasmic domain (17,
18). Transfection experiments and studies with purified
DO–DM complexes have demonstrated that DO is a nega-
tive regulator of DM catalytic activity (19–22), although
there is one report that DO can enhance DM function
(23). DO does not completely inhibit DM function, but
rather limits the pH range in which DM is active (21, 22).
By limiting DM function in all but the most acidic endoso-
mal compartments in B cells, DO might serve to promote
the presentation of peptides derived from antigens internal-
ized through the B cell antigen receptor (BCR), which is
preferentially targeted to lysosomal compartments (21, 22).
It is appealing to consider the idea that DO may also
provide a mechanism to rapidly up-regulate DM activity
(24). However, no previous evidence has been provided
indicating that DO can be released from DM, or that the
ratio of free DM to DM–DO complexes can be modulated
in B cells, for example, by activation. Indeed, the fraction
of DM molecules bound to DO in primary B cells has not
been determined and it is not clear whether DO has a ma-
jor impact on DM activity in normal B cells. In the present
study, we describe the expression of DO in human periph-
eral blood cells, bone marrow, and secondary lymphoid tis-
sue. Our results demonstrate that DO is selectively ex-
pressed in B cells, a major fraction of DM molecules is
bound to DO in these cells, and DO expression is modu-
lated during both the antigen-dependent and -independent
phases of B cell development.
 
Materials and Methods
 
Cells.
 
Fresh or frozen lymph node cells were derived from
healthy cadaveric organ donors. Peripheral blood specimens were
derived from the same sources or healthy blood donors. Bone
marrow cells were derived from bone marrow aspiration of pa-
tients whose specimens were received for pathological evaluation
to rule out hematological disorders and diagnosed as “no diagnos-
tic pathology or unremarkable.” Fresh tonsil cells for flow cytom-
etry analysis were derived from tonsillectomy specimens. The
presence of germinal centers (GCs) in the tonsils was confirmed
by subsequent histological evaluation. Peripheral blood mononu-
cleated lymphoid cells were isolated by Ficoll-Paque density gra-
dient (Amersham Pharmacia Biotech). Single cell suspensions of
lymphoid tissues and peripheral blood mononucleated lymphoid
cells were prepared for four-color flow cytometry analysis.
 
Antibodies and Flow Cytometry.
 
Chromogen-conjugated mAb
to CD19 (HIB19), CD38 (HIT2), IgD (IA6-2), IgM (G20-127),
CLIP (CerCLIP), and HLA-DM (MapDM1); and CD34 (581),
CD45 (HI30), CD3 (UCHT1), CD5 (L17F12), HLA-DR
(L243), CD14 (M5E2), CD10 (HI10a), and isotype-matched
negative control mAbs were purchased from BD PharMingen.
Biotinylated CerCLIP antibody was produced in the laboratory at
the Emory University School of Medicine. mAb to HLA-DO
 
 
 
cytoplasmic domain, DOB.L1 (23), provided by H. Kropshofer
and A. Vogt (Basel Institute for Immunology, Basel, Switzerland),
was FITC conjugated in this laboratory. PE-conjugated mAb to
DO was purchased from BD PharMingen. Cell surface staining
 
was performed with a combination of four of each FITC, PE,
PerCP, or APC-labeled mAbs according to the standard proce-
dures. Intracellular staining was performed using Fix & Perm kits
(Caltag Laboratory) according to the manufacturer’s instructions.
In brief, cells were washed with 1% PBS–BSA after surface stain-
ing and fixed with medium A for 15 min at room temperature.
Cells were then thoroughly washed with 1% PBS–BSA and incu-
bated in medium B containing DM or DO antibodies for 15 min
at room temperature, followed by washing with 1% PBS–BSA.
Stained cells were analyzed on a FACS
 
®
 
 Calibur (Becton Dickin-
son). 10,000–20,000 events were collected per dot plot.
 
Immunohistochemistry.
 
Representative formalin-fixed, paraf-
fin-embedded tissue sections of tonsillectomy specimens were de-
waxed and subjected to antigen retrieval in citrate buffer, pH 6,
using an electric pressure cooker (Biocare Medical) set at 120
 
 
 
C
for 5 min (25). Sections were incubated for 5 min in 3% hydro-
gen peroxide. Immunohistochemistry was performed using pri-
mary antibodies directed against DO (DOB.L1), DM
 
 
 
 cytoplas-
mic domain (clone 4.7GS; provided by S. Pierce, National
Institutes of Health, National Institute of Allergy and Infectious
Diseases, Rockville, MD), CD10 (56c6; Novocastra), DR
(TAL.1B5; Dako), CD20 (Bly1; Dako), CD3 (T3-4B5; Dako),
and Mib-1/Ki-67 (Mib-1; Dako). After 25-min incubations with
primary antibody, sections were washed and treated with com-
mercial biotinylated secondary anti-immunoglobulin, followed
by avidin coupled to biotinylated horseradish peroxidase, accord-
ing to the manufacturer’s instructions (LSAB2 kit for mouse pri-
mary antibodies; Dako). The immunohistochemical reactions
were visualized using diaminobenzidine as a chromogenic perox-
idase substrate. Sections were counterstained with hematoxylin.
 
Immunoprecipitation and Western Blot Analysis.
 
CD14
 
 
 
 mono-
cytes and CD19
 
 
 
 B cells were isolated from PBMC using the
MACS
 
®
 
 separation system (Miltenyi Biotec) according to the
manufacturer’s guidelines. In brief, blood mononuclear cells frac-
tionated via Ficoll-Paque density gradient were resuspended in
MACS
 
®
 
 buffer (PBS without Ca
 
2
 
  
 
supplemented with 0.5% BSA
and 2 mM EDTA) containing the appropriate amount of anti-
CD14 or anti-CD19 antibody-conjugated magnetic microbeads.
After 30 min of incubation on ice, CD14
 
 
 
 and CD19
 
 
 
 cells were
isolated from the cell suspensions using an LS
 
 
 
 column (Miltenyi
Biotec). Greater than 95% of the purity of the cell separations was
confirmed by flow cytometry. To generate dendritic cells,
CD14
 
 
 
 cells were resuspended in RPMI 1640 (10% FCS, 100
U/ml penicillin, and 100 U/ml streptomycin; Life Technologies)
containing 10 ng/ml rhIL-4 and 10 ng/ml rhGM-CSF (Pepro-
Tech) and cultured for 6 d. Mature dendritic cells were generated
by stimulating the immature dendritic cells with 100 ng/ml LPS
for 24 h. For immunoprecipitation and immunodepletion exper-
iments, 5 
 
  
 
10
 
6
 
 cells were lysed in 0.25 ml of lysis buffer (PBS,
1% CHAPS, 1 mM DTT, 20 
 
 
 
M p-APMSF, and 1 mM EDTA)
for 30–40 min. After clarification in a microfuge for 10 min at
14,000 rpm, the lysates were incubated for 1.5 h on a rotating
platform at 4
 
 
 
C with specific antibody (6 
 
 
 
g per sample), fol-
lowed by incubation with 60 
 
 
 
l of the protein A–Sepharose
(Amersham Pharmacia Biotech) for 1 h. The protein A–Sepharose
pellet was washed six times at room temperature with 1 ml of the
washing buffer (PBS, 0.5% CHAPS) and resuspended in 30 
 
 
 
l of
Laemmli buffer followed by SDS-PAGE. The primary mAbs
used in the immunoprecipitation and Western blot experiments
were DOB.L1 (23) against HLA-DO
 
 
 
 cytoplasmic domain,
4.G7S against HLA-DM
 
 
 
 cytoplasmic domain, 9E10 against
c-MYC epitope (American Type Culture Collection), and poly-
clonal rabbit antisera to HLA-DR
 
  
 
. 
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GC and non-GC B cells were isolated from single cell suspen-
sions of human tonsils. Cells were first stained with 10 
 
 
 
g/ml of
mouse anti–human CD10 mAb (HI10a/IgG1-
 
 
 
; BD PharMin-
gen) followed by MACS
 
®
 
 rat anti–mouse IgG1 MicroBeads
(Miltenyi Biotec). CD10
 
 
 
 cells were selected by passing cell sus-
pension through a magnetic separator (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions. The CD10-depleted tonsil
cells were then stained with MACS
 
®
 
 anti-CD19 MicroBeads,
and CD19
 
 
 
 cells were selected using the magnetic separator. The
purity of each cell preparation was evaluated by flow cytometry.
 
Results
 
Expression of HLA-DO in Peripheral Blood B Cells but Not
Monocytes or Dendritic Cells.
 
Cell surface CLIP expression
serves as a surrogate marker of HLA-DM function in APC.
DM is required for the efficient release of CLIP from
MHC class II molecules and high concentrations of CLIP–
class II complexes are present on the surface of DM-defi-
cient APC (2, 3, 9–11). We observed that CLIP is readily
detected on peripheral blood B cells by flow cytometry,
whereas relatively little CLIP is detected on monocytes
(Fig. 1 a). There is considerable variation in the levels of
CLIP expressed on B cells from different donors, probably
due to differences in the stability of the binding of CLIP to
different DR allotypes. However, CLIP expression is al-
ways much lower on monocytes. Surface HLA-DR ex-
pression is also lower on monocytes compared to B cells,
but the reduction in DR is insufficient to account for the
difference in CLIP expression. Based on the analysis of 15
independent samples, the mean fluorescence intensity of
DR staining was 824 
 
 
 
 281 (B cells) and 489 
 
 
 
 251
(monocytes). By contrast, the mean fluorescence intensity
of CLIP staining was 331 
 
 
 
 98 (B cells) and 16 
 
 
 
 9
(monocytes). The possibility that reduced HLA-DM ex-
pression could account for higher CLIP levels in B cells
was addressed by intracellular staining. DM expression was
observed to be one- to threefold higher in B cells com-
pared to monocytes, depending on the sample (Fig. 1 a).
By contrast, HLA-DO expression was only observed in B
cells and not in monocytes. The latter result was confirmed
by Western blot analysis of lysates of purified B cells and
monocytes (Fig. 1 b). Notably, DO expression was unde-
tectable in immature and LPS-activated monocyte-derived
dendritic cells by Western blot analysis (Fig. 1 b) and flow
cytometry (unpublished data), despite very high expression
levels of DR (unpublished data) and DM (Fig. 1 b). These
results demonstrated a correlation between CLIP expres-
sion and DO expression in DR
 
 
 
 peripheral blood mono-
nuclear cells, which suggests that DO functions specifically
in B cells to inhibit DM activity.
 
Fraction of HLA-DM Molecules Bound to HLA-DO in Pri-
mary B Cells.
 
Available evidence indicates that HLA-DO
molecules are unstable in the absence of DM and that all
DO present in post-Golgi compartments is stably bound to
DM (17). Kropshofer et al. (23) reported that 60–70% of
DM molecules in the WT-100 human B cell line are copre-
cipitated with mAb to DO. However, the fraction of DM
molecules bound to DO in primary B cells has not been re-
ported. This is an important issue when considering the po-
tential biological roles for DO. If only a small fraction of
DM molecules are occupied by DO, one must seriously
consider the possibility that DO has some unique function
other than inhibiting DM activity. We addressed this issue
by preclearing detergent lysates of B cells with anti-DO
mAb and measuring residual free DM in Western blots. As
demonstrated in Fig. 2 a, a substantial fraction of total DM
in the Raji B cell line is removed by depletion with anti-
bodies to DO. Titration of lysates precleared with anti-DO
versus control antibody demonstrated that 
 
 
 
50% of DM in
Raji cells is stably bound to DO. Similar experiments were
performed with purified peripheral blood B cells, demon-
strating that 
 
 
 
50% of DM is stably bound to DO in these
cells (Fig. 2 b). We conclude that a substantial fraction of
DM is associated with DO in primary human B cells.
 
HLA-DO Expression Occurs Late During B Cell Develop-
ment in Adult Human Bone Marrow.
 
It has previously been
demonstrated that MHC class II molecules are not ex-
pressed on pro-B cells in fetal mice, but rather in adult
mice (26, 27). We were interested in determining if com-
ponents of the class II antigen–processing pathway are ex-
pressed in human B cell precursors. Pro-B (CD19
 
 
 
CD10
 
 
 
CD34
 
 
 
) and pre-B (CD19
 
 
 
CD10
 
 
 
CD34
 
 
 
) popu-
lations (28) can be distinguished from B cells (CD19
 
 
 
CD10
 
 
 
CD34
 
 
 
) by differential expression of CD45 (Fig. 3,
Figure 1. Expression of HLA-DO in peripheral blood B cells but not
in monocytes or dendritic cells. (a) Analysis of CLIP, DR, DM, and DO
expression in B cells (CD19 ) versus monocytes (CD14 ) using four-
color flow cytometry. DM and DO expression were measured by staining
permeabilized cells as previously described in Materials and Methods. (b)
DM and DO expression in purified B lymphocytes (B), monocytes (M),
immature dendritic cells (DC), and mature dendritic cells (DC*) were
evaluated by Western blot analysis as previously described in Materials
and Methods. Numbers indicate the quantity (cell equivalents   10 4)
loaded in each lane. Blots were developed with anti–HLA-DM (4.G7S)
and anti–HLA-DO (DOB.L1) mAb. 
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top). As illustrated in Fig. 3, all CD19
 
 
 
 B lineage cells in
adult human bone marrow express HLA-DR, although it is
clearly up-regulated at the pro-B (R2) to pre-B (R3) tran-
sition. Pre-B cells express DR at a level similar to B cells
(R4). Remarkably, CLIP expression is largely limited to B
cells, with little or no expression on B cell precursors. In-
tracellular staining demonstrates that all CD19
 
 
 
 B lineage
cells express DM. Two distinct populations are observed,
which express low versus high levels of DM. Pro-B and
pre-B cells uniformly express low DM, whereas B cells are
divided into both groups. A minority of B cells express low
DM and the major population expresses high DM. By con-
trast, DO is only expressed in B cells and is not detected in
B cell precursors.
A subpopulation of the B cells is negative for DO, as il-
lustrated in Fig. 3. Notably, all B cells that express high lev-
els of DM also express DO, whereas cells with lower DM
expression are negative for DO. Using CD10 expression to
distinguish immature (CD10
 
 
 
) and mature (CD10
 
 
 
) B
cells, we observed that DO up-regulation occurs at the
transition from immature to mature B cells. Both popula-
tions express similar levels of surface IgM. CLIP expression
is also substantially up-regulated at the transition from im-
mature to mature B cells. Thus we conclude that both DR
and DM are expressed beginning at the pro-B stage,
whereas DO protein expression is initiated only after B cell
maturation is complete. In addition, these results provide
another example of a correlation between the expression of
DO and CLIP, adding support to the hypothesis that DO
has a substantial impact on DM functional activity in pri-
mary human B cells.
 
Expression of HLA-DO Is Down-regulated in GC B
Cells.
 
The major role of the antigen-processing and pre-
sentation pathway in B cells is to provide a mechanism for
cognate T–B cell interactions, which are required to drive
T cell–dependent humoral immune responses. These inter-
actions occur in secondary lymphoid tissues and are re-
quired for the initiation, and possibly propagation, of GC
reactions. We were interested in the possibility that DO
expression might be modulated during antigen-driven B
cell differentiation. Strikingly, immunohistochemistry ex-
periments with human tonsil demonstrated that DO ex-
pression was markedly reduced in GC B cells. In these
studies, DO was detected only in a few scattered cells in the
GC, whereas mantle zone B cells and B cells in other sites
were strongly positive (Fig. 4). Similar results were ob-
tained in a reactive lymph node sample (unpublished data).
By immunohistochemistry, human GC B cells, which can
be distinguished by CD10 expression, express both DR
and DM, although DM expression appears to be lower in
GC B cells compared to non-GC B cells. Both highly pro-
liferating Mib-1
 
 
 
 centroblasts (29) and Mib-1
 
 
 
 centrocytes
down-regulate DO.
DO expression is markedly reduced but not absent in
CD19
 
 
 
CD10
 
 
 
 GC B cells, as judged by flow cytometry
(Fig. 5, top). A small fraction of GC B cells express DO at
levels similar to CD19
 
 
 
CD10
 
 
 
 non-GC B cells. These
probably correspond to the scattered DO
 
 
 
 cells observed in
Figure 2. Fraction of HLA-DM molecules bound to HLA-DO in B
cells. (a) The top panels (lysates) show Western blot analysis of Raji B cell
lysates before or after preclearing with anti-DO or control mAb, as indi-
cated. The middle panels (IP) show Western blot analysis of immunopre-
cipitates generated with the anti-DO (DOB.L1) or control mAb. Blots
were stained with mAb 4.7GS (DM) or DOB.L1 (DO). The bottom
panels show DM Western blot analysis of titrations of Raji cell extracts
depleted with anti–HLA-DO or with control antibody. Numbers indi-
cate sample quantity (cell equivalents   10 4) loaded in each lane. (b)
Similar analysis with purified peripheral blood B cells. 
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GCs by immunohistochemistry. DM expression is slightly
reduced but there is substantial overlap in the fluorescence
intensities of the GC and non-GC B cells. GC and non-
GC B cells were purified and analyzed in Western blots to
obtain a firmer estimation of the relative extent of down-
regulation of DO and DM. DR and DM expression levels
were similar in the two populations (Fig. 6). By contrast,
DO expression was markedly reduced in GC B cells. DO
protein expression is reduced at least threefold based on
comparison of titrated quantities of cell lysates.
The fraction of DR molecules bearing CLIP is reduced
in GC B cells as determined by flow cytometry. This is
best illustrated by comparing the two populations in a plot
of DR versus CLIP staining (Fig. 5). There is a wide distri-
bution of DR expression levels in each population, but
CLIP expression is always reduced on GC B cells com-
pared to non-GC B cells expressing similar levels of DR.
Thus, net DM functional activity appears to be increased
in GC B cells. Notably, GC B cells up-regulate expression
of the costimulatory molecules CD80 and CD86, as well
as CD40, supporting a possible role for GC B cells as APC
(Fig. 5).
The scattered high DO B cells in the GC could repre-
sent cells that recently entered the GC and have yet to
down-regulate DO, or cells that up-regulate DO expres-
sion before exiting the GC. IgD and CD38 can be used as
cell surface markers to define discrete subpopulations of
human tonsillar B cells (30). As shown in Fig. 7, DM ex-
pression is essentially constant in tonsillar B cell subpopula-
tions. IgD
 
 
 
CD38
 
 
 
 naive follicular mantle B cells uni-
formly express DO at levels similar to peripheral blood B
cells. By contrast, DO expression is uniformly reduced in
classic IgD
 
 
 
CD38
 
 
 
 GC B cells, which include both cen-
troblasts and centrocytes. The IgD
 
 
 
CD38
 
 
 
 subpopulation
has been proposed to include the GC founder cells based
on several criteria, including the coexpression of naive B
Figure 3. Expression of the
components of the class II anti-
gen–processing pathway during
B cell development in adult hu-
man bone marrow. The top pan-
els show pro-B (R2; CD19 
CD45lowCD34 CD10 ), pre-B
(R3; CD45intermediateCD19 
CD34 CD10 ), and B cell (R4;
CD19 CD45highCD34 CD10 
or CD10 ) subpopulations as de-
fined by four-color flow cytom-
etry. The other panels show the
expression of CLIP, DR, DM,
and DO in these three subpopu-
lations (DM and DO were mea-
sured by staining permeabilized
cells). B cells (R4) are addition-
ally analyzed for DO expression
based on the expression of
CD10. The bottom panels show
CLIP and DR expression in
CD10  (pro-B, pre-B, and imma-
ture B cells) and CD10  (mature
B cells). 
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cell markers and GC markers, and low levels of IgV gene
mutations (30). It is interesting that there appears to be an
intermediate level of expression of DO with a possible bi-
modal distribution in the IgD
 
 
 
CD38
 
 
 
 population (Fig. 7).
This needs further investigation, but it raises the possibility
that DO expression is down-regulated during the founder
cell stage after entry into GC and before the loss of surface
IgD expression. High DO expression is observed in the
IgD
 
 
 
CD38
 
 
 
 subpopulation and believed to represent
memory cells. Thus, DO expression is up-regulated at the
transition from GC to memory B cells.
 
Discussion
 
In this study, we demonstrate that HLA-DO is not a
static component of the B cell antigen-processing pathway,
but instead show that its expression is regulated in both the
antigen-dependent and antigen-independent phases of B
cell development. Intracellular flow cytometry and West-
ern blot analysis of human peripheral blood cells were used
to demonstrate that DO is selectively expressed in B cells
and not in monocytes. In addition, CD11c  dendritic cells
derived by culturing peripheral blood monocytes with
GM-CSF and IL-4, are negative for DO before and after
activation with LPS. This result contrasts with a previous
report showing DO expression in GM-CSF–induced hu-
man dendritic cells (31). Our results support the conclusion
that DO is selectively expressed in B cells and not in other
peripheral APC in humans.
The fraction of DM molecules stably associated with DO
in B cells is a key issue in considering the potential func-
tions of DO. Our results suggest that  50% of DM mole-
cules are bound to DO in the Raji cell line and in periph-
eral blood B cells. This could be an underestimate
Figure 4. Downmodulation of
DO expression in GC B cells. GCs
in human tonsil tissue sections
were analyzed by immunohis-
tochemistry with mAb specific for
the indicated markers. The pattern
of staining for each marker is repre-
sentative of all GCs in the section.
Figure 5. Expression of HLA-DO in cells from human tonsil. GC B cells (R2; CD19 CD10 ) express substantially lower levels of DO compared to
non-GC B cells (R3; CD19 CD10 ) as determined by intracellular staining and four-color flow cytometry. Results are representative of eight tonsillec-
tomy specimens.1059 Chen et al.
depending on the extent that DM–DO complexes dissoci-
ate in cell lysates during detergent solubilization and immu-
noprecipitation. This estimate represents the total cellular
pool. It is possible that the proportion of free DM may vary
in different subcellular compartments (23, 32), or between
limiting and internal membrane structures of lysosome-
related peptide loading compartments (33). Nevertheless,
this is an important result. If only a small fraction of DM mol-
ecules were bound to DO, one would conclude that DO or
DO–DM complexes might have some novel function
other than inhibiting DM activity. It appears, however,
that a substantial fraction of DM molecules in B cells are
not bound to DO. It is not known whether there is an ex-
cess of DM in B cells. Therefore, removing half of the DM
activity would have little impact on peptide loading activ-
ity. Based on previous work, we would predict that a 50%
reduction in the concentration of functional DM would be
associated with a proportional decrease in DM-catalyzed
peptide exchange activity (12). B cells from heterozygous
H2-M /  mice express elevated cell surface class II–CLIP
complexes (10, 11), suggesting that a twofold reduction in
H2-M has a substantial impact on the catalytic function in
B cells from this species. The results presented here provide
correlative evidence that physiological levels of DO expres-
sion inhibit net DM functional activity in primary human
B cells, extending previous studies with transfected cell
lines (19, 20, 22). In any given individual, CLIP expression
is substantially higher on B cells than monocytes, despite
expression of the same array of MHC class II molecules and
similar levels of DM. There is a striking relationship be-
tween DO expression and CLIP expression during B cell
development in adult human bone marrow. Pre-B cells ex-
press similar levels of DR and lower levels of DM than B
cells, yet CLIP expression is markedly higher in B cells,
which correlates with the initiation of DO expression. This
relationship is also observed with GC B cells, in which
downmodulation of DO is associated with a reduction in
the fraction of DR molecules bearing CLIP. In addition,
occult follicular lymphoma cells in a lymph node sample
were observed to express similar levels of DM and DR, but
elevated levels of DO and CLIP compared to normal B
cells in the same sample (unpublished data). These results
support the conclusion that DO expression has a major im-
pact on net DM activity in primary human B cells. Thus, a
substantial fraction of DR molecules do not undergo the
first round of DM-catalyzed peptide exchange required to
release CLIP. The impact of H2-O may not be as great in
mouse B cells, because CLIP expression is low, even on B
cells from strains expressing class II molecules with high af-
finity for CLIP (21). However, as noted, CLIP expression
is prominent in B cells from H2-M /  heterozygotes.
Thus, net H2-M activity cannot be far in excess of that re-
quired to efficiently mediate CLIP release, and it is likely
that subsequent rounds of H2-M–catalyzed peptide ex-
change are attenuated in mouse B cells.
The observation that adult bone marrow pro-B and
pre-B cells express DR and DM suggests that these cells
may have a fully functional MHC class II antigen–processing
Figure 6. Western blot analysis of GC B cells. GC (CD10 CD19 )
and non-GC (CD10 CD19 ) B cells were purified from human tonsil as
previously described in Materials and Methods. The top panels show flow
cytometric analysis of the purified populations. The lower panels show
Western blot analysis of DR, DM, and DO expression in CD10  and
CD10  B cells. Blots were stained with polyclonal rabbit antiserum
(DR), mAb 4.7GS (DM), or DOB.L1 (DO). Numbers indicate sample
quantity (cell equivalent   10 4) loaded in each lane. Figure 7. Analysis of DO expression in tonsillar B cell subpopulations.
Samples gated on CD19  lymphocytes were subdivided based on the ex-
pression of IgD and CD38. Mature naive B (IgD CD38 ) and memory
B cells (IgD CD38 ) express high levels of DO by intracellular flow cy-
tometry. DO expression is substantially reduced in classical GC B cells
(IgD CD38 ). DO expression is intermediate or heterogeneous in
IgD CD38  cells, which include GC founder cells. DM expression is
similar in all subpopulations.1060 Regulated Expression of HLA-DO
pathway. There is no evidence that T cells play a role in
the antigen-independent phases of B cell development. It is
possible that the antigen presentation machinery in these
cells is superfluous, a byproduct of the transcriptional pro-
gram during B cell development with no functional conse-
quences. Alternatively, antigen presentation by B cell pre-
cursors could have some undiscovered role, for example,
inducing T cell tolerance to B cell antigens. T cells are
present in bone marrow, but their origin and function are
poorly understood. B cell precursors do not express costim-
ulatory molecules and CD40 is not expressed until the ma-
ture B cell stage (unpublished data). Therefore, interaction
with these cells is likely to result in T cell anergy rather
than activation. It is particularly interesting to consider the
phenotype of immature B cells, which express high levels
of DM and DR, but no DO. At this stage, B lineage cells
first express BCR (mIgM), providing the potential for
BCR-mediated internalization of specific antigen and effi-
cient presentation to cognate T cells. B cells undergo nega-
tive and positive selection at this stage (34, 35). A subpopu-
lation of immature cells leaves the bone marrow the same
way as transitional B cells that have the potential for inter-
actions with T cells in the spleen (36–39). It is possible that
in the presence of antigen, interactions with activated cog-
nate CD4  T cells might rescue transitional B cells from
deletion and promote their recruitment into follicles or
GC. In the absence of DO, DM-mediated peptide loading
activity might be elevated in immature B cells, increasing
the efficiency of antigen processing and compensating for a
reduced capacity for BCR-mediated endocytosis resulting
from the relatively low expression of total mIg on these
IgD  cells. These ideas will require further investigation.
It is striking that the only physiological situation identi-
fied so far in which DO expression is down-regulated in
mature B cells is in the context of the GC reaction. DO
expression is substantially reduced in GC B cells as deter-
mined by immunohistochemistry, flow cytometry, and
Western blot analysis. This is true for both centroblasts and
centrocytes. By contrast, DM and DR expression levels are
very similar in GC and non-GC B cells. There appears to
be a marginal reduction in the average DM expression and
a slight elevation in the average DR expression. The
marked reduction in DO expression appears to be associ-
ated with an increase in DM functional activity, as judged
by a reduction in CLIP–DR complexes on the surface of
GC B cells. We cannot rule out the possibility that compo-
nents of the antigen-processing pathway, other than DO,
are significantly modulated in GC B cells and that this
could potentially affect CLIP expression.
The primary role of antigen presentation by B cells is to
provide a mechanism to orchestrate selective interactions
between B cells and T cells sharing antigen specificity. B
cells do not appear to play an important role in activating
naive T cells or amplifying CD4  T cell responses. Cog-
nate T–B cell interactions, dependent upon antigen pro-
cessing and presentation by B cells, are required to generate
GC and drive Ig class switching, somatic hypermutation,
and the generation of memory B cells and long-lived
plasma cells (40). It is believed that the initial encounter
with antigen promotes the migration of B cells from the
center of B cell follicles in secondary lymphoid organs to
the boundary between the B and T cell zones (41–44). Af-
ter receiving signals through cognate interaction with pre-
viously activated CD4  T cells, some B cells move back
into the center of the B cell follicle and begin a process of
rapid proliferation that, over the course of 4–6 d, results in
the formation of histologically distinct GC. At what point
in this sequence of events is DO expression downmodu-
lated? Our results demonstrate that DO expression is uni-
formly low in classical IgD CD38  GC cells. However,
the IgD CD38  population in tonsils, believed to include
GC founder cells (30), appears to have an intermediate
level of expression of DO with a possible bimodal distribu-
tion. Thus, it is possible that DO down-regulation occurs
after the initial entry of founder cells into the GC, but be-
fore the loss of surface IgD. This would imply that the ini-
tial T–B cell interaction, leading to the commitment of the
B cell to the GC reaction, occurs before the reduction of
DO expression. Alternatively, BCR ligation with antigen
in the context of the follicle microenvironment might in-
duce DO down-regulation before the initial T cell interac-
tion. The IgD CD38  population in tonsil includes an un-
usual subset of IgM  cells with a high frequency of Ig
mutations (30). The possibility that these cells account for
the high DO subpopulation of IgD CD38  cells, and that
founder cells have uniformly low DO expression, is under
investigation. If the latter scenario is correct, DO may be
downmodulated before the initial encounter with T cells,
providing a means of up-regulating peptide loading and an-
tigen presentation by B cells as a consequence of antigen
encounter in the follicle microenvironment.
If DO expression is reduced only after the critical anti-
gen presentation event that results in commitment to the
GC reaction, what role might the consequent modulation
of the antigen-processing function have in B cell immune
responses? Antigen presentation by GC B cells and cognate
interactions with T cells could play an important role in
driving the continued proliferation and somatic mutation
in centroblasts. Alternatively, competition between centro-
cytes for successful interactions with a limited number of T
cells in the GC might play a role in promoting survival and
antigen-driven selection in GC. Centrocytes expressing
higher affinity BCR would have a competitive advantage
internalizing and processing limited quantities of antigen.
Total surface BCR expression is markedly reduced in GC B
cells because of the loss of expression of IgD, reducing the
potential efficiency of BCR-mediated endocytosis. The re-
duction in DO expression and consequent up-regulation of
DM function might compensate to increase the efficiency
of antigen processing in GC B cells. In favor of a role for
antigen presentation by GC B cells is the observation that
the blockade of CD40–CD40L interactions not only inhib-
its formation of GC, but also results in the dissolution of
GC after they are established (45, 46). In addition, the
blockade of CD86 was reported to inhibit Ig hypermuta-
tion and memory development in established GC (46). As1061 Chen et al.
shown in Fig. 5, GC B cells express increased levels of DR,
CD80, and CD86, additionally supporting a role for GC B
cells in antigen presentation.
An appealing hypothesis is that the function of DO is to
attenuate or limit the antigen-processing function of B cells
in all situations outside of the protected environment of the
GC. IgD CD38  cells in tonsil uniformly express a high
level of DO, similar to naive B cells. This indicates that
DO expression is up-regulated in memory B cells before or
immediately after exiting GC. DO might simply attenuate
the antigen-processing function in non-GC B cells, or it
may serve to selectively limit the presentation of peptides
derived from antigens internalized through non-BCR–
mediated mechanisms (21). Through either mechanism, it
may help to prevent aberrant or bystander T–B cell inter-
actions. This protective mechanism may no longer be nec-
essary or desirable in the context of the GC reaction, where
contact with T cells is anatomically segregated and limited
to a small population of GC T cells that share specificity for
common antigens.
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